Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study

PURPOSE: Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Kang, Jian, Wang, Changzheng, Yang, Jing, Wang, Linda, Kottakis, Ioannis, Humphries, Michael, Zhong, Nanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853509/
https://www.ncbi.nlm.nih.gov/pubmed/27126725
http://dx.doi.org/10.4168/aair.2016.8.4.319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853509/
https://www.ncbi.nlm.nih.gov/pubmed/27126725
http://dx.doi.org/10.4168/aair.2016.8.4.319

Ejemplares similares